Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3

Status

Completed 5Withdrawn 1

Sponsor Class

OTHER 6NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Myeloid 13Other hematologic neoplasm 10Head & Neck 10CNS 9Sarcoma 6Gastrointestinal 3Lymphoid 2Other solid neoplasm 1

Conditions

Gliosarcoma 5Glioblastoma 5Brain Neoplasms 5Glioma 2Oligodendroglioma 1Meningioma 1Fibroma 1Ependymoma 1Desmoid Tumors 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

Radiotherapy 137Cyclophosphamide 132Temozolomide 116Doxorubicin 99Filgrastim 68Ifosfamide 64Gemcitabine 58Etoposide 55Bevacizumab 51Imatinib Mesylate 50fludarabine phosphate 49Irinotecan 46pembrolizumab 45Peripheral Blood Stem Cell Transplantation 45pazopanib 43Magnetic Resonance Spectroscopy 42Methotrexate 40Carboplatin 40Busulfan 40Vincristine 38Surgical Procedures, Operative 37Nivolumab 37Melphalan 37Cisplatin 36Radiation 34Blood Specimen Collection 33Mycophenolic Acid 31Cyclosporine 31Docetaxel 29Trabectedin 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × Hydroxyurea × Sarcoma × Clear all
NCT00978146 2017-04-20

Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors

Children's Hospital of Philadelphia

Phase 2 Withdrawn
Sarcoma

Fibroma, Desmoid Tumors

NCT00387933 2015-10-14

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Duke University

Phase 1 Completed
37 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00615927 2013-03-15

Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)

Duke University

Phase 2 Completed
64 enrolled 9 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00613132 2013-02-20

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

Duke University

Phase 1 Completed
78 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00354913 2013-01-18

Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

Duke University

Phase 2 Completed
21 enrolled 8 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Meningioma, Gliosarcoma

NCT00613054 2012-12-05

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

Duke University

Phase 1 Completed
27 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡